IL103665A - Analogues of sulfasalazine and their use in the preparation of a medicament having therapeutic effect against autoimmune diseases - Google Patents

Analogues of sulfasalazine and their use in the preparation of a medicament having therapeutic effect against autoimmune diseases

Info

Publication number
IL103665A
IL103665A IL10366592A IL10366592A IL103665A IL 103665 A IL103665 A IL 103665A IL 10366592 A IL10366592 A IL 10366592A IL 10366592 A IL10366592 A IL 10366592A IL 103665 A IL103665 A IL 103665A
Authority
IL
Israel
Prior art keywords
compound
preparation
autoimmune diseases
sulfasalazine
analogues
Prior art date
Application number
IL10366592A
Other languages
English (en)
Other versions
IL103665A0 (en
Inventor
Karl H Agback
Leif Ahrgren
Thomas Berglindh
Martin Haraldsson
Lars-Inge Olsson
Rd Goeran Smedeg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of IL103665A0 publication Critical patent/IL103665A0/xx
Publication of IL103665A publication Critical patent/IL103665A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
IL10366592A 1991-11-18 1992-11-06 Analogues of sulfasalazine and their use in the preparation of a medicament having therapeutic effect against autoimmune diseases IL103665A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror

Publications (2)

Publication Number Publication Date
IL103665A0 IL103665A0 (en) 1993-04-04
IL103665A true IL103665A (en) 1997-08-14

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10366592A IL103665A (en) 1991-11-18 1992-11-06 Analogues of sulfasalazine and their use in the preparation of a medicament having therapeutic effect against autoimmune diseases

Country Status (29)

Country Link
US (3) US5302718A (xx)
EP (1) EP0613468B1 (xx)
JP (1) JP3259915B2 (xx)
KR (1) KR100253748B1 (xx)
AT (1) ATE194597T1 (xx)
AU (1) AU668528B2 (xx)
CA (1) CA2123697C (xx)
DE (1) DE69231252T2 (xx)
DK (1) DK0613468T3 (xx)
EE (1) EE03026B1 (xx)
ES (1) ES2149780T3 (xx)
FI (1) FI106857B (xx)
GR (1) GR3034585T3 (xx)
HU (2) HU221476B (xx)
IL (1) IL103665A (xx)
LT (1) LT3182B (xx)
LV (1) LV10246B (xx)
MX (1) MX9206647A (xx)
MY (1) MY130169A (xx)
NO (1) NO300805B1 (xx)
NZ (1) NZ244998A (xx)
PT (1) PT101068B (xx)
RU (1) RU2124501C1 (xx)
SE (1) SE9103397D0 (xx)
SK (1) SK282080B6 (xx)
TW (1) TW304944B (xx)
UA (1) UA42869C2 (xx)
WO (1) WO1993010094A1 (xx)
ZA (1) ZA928864B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
WO1997010813A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
IL124542A (en) 1996-02-20 2003-07-06 Bristol Myers Squibb Co Method for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
WO1999063980A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
KR20020004974A (ko) 1999-03-19 2002-01-16 스티븐 비. 데이비스 비페닐 이속사졸 술폰아미드의 제조방법
NZ517147A (en) 1999-09-04 2003-11-28 Astrazeneca Ab Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
ATE399753T1 (de) 1999-09-04 2008-07-15 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
DE60031699T2 (de) 1999-09-04 2007-08-30 Astrazeneca Ab Hydroxyacetamidobenzolsulfonamidderivate
DE60115414D1 (de) * 2000-04-28 2006-01-05 Univ British Columbia N-heterosubstituierten salicylaten zur behandlung von krebs
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
OA13344A (en) * 2003-12-19 2007-04-13 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity.
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
CA2643963A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2009263457B2 (en) * 2008-06-23 2013-05-16 Astellas Pharma Inc. Sulfonamide compounds or salts thereof
AU2012220620A1 (en) * 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
SI3300500T1 (sl) 2015-05-20 2020-07-31 Amgen Inc. Triazolni agonisti receptorja APJ
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
MX9206647A (es) 1993-05-01
HU221476B (en) 2002-10-28
KR100253748B1 (ko) 2000-05-01
WO1993010094A1 (en) 1993-05-27
FI942289A0 (fi) 1994-05-17
UA42869C2 (uk) 2001-11-15
LTIP229A (en) 1994-09-25
ATE194597T1 (de) 2000-07-15
IL103665A0 (en) 1993-04-04
US5403930A (en) 1995-04-04
FI942289A (fi) 1994-05-17
DE69231252T2 (de) 2001-03-01
HU211163A9 (en) 1995-10-30
SK282080B6 (sk) 2001-10-08
RU2124501C1 (ru) 1999-01-10
AU668528B2 (en) 1996-05-09
LV10246B (en) 1995-04-20
CA2123697C (en) 2003-12-09
SK54794A3 (en) 1995-02-08
NZ244998A (en) 1995-09-26
TW304944B (xx) 1997-05-11
JPH07501330A (ja) 1995-02-09
NO300805B1 (no) 1997-07-28
CA2123697A1 (en) 1993-05-27
EP0613468A1 (en) 1994-09-07
DK0613468T3 (da) 2000-10-23
DE69231252D1 (de) 2000-08-17
ES2149780T3 (es) 2000-11-16
US5302718A (en) 1994-04-12
SE9103397D0 (sv) 1991-11-18
LV10246A (lv) 1994-10-20
GR3034585T3 (en) 2001-01-31
JP3259915B2 (ja) 2002-02-25
AU2958992A (en) 1993-06-15
EE03026B1 (et) 1997-08-15
FI106857B (fi) 2001-04-30
NO941799D0 (no) 1994-05-13
HUT69723A (en) 1995-09-28
LT3182B (en) 1995-03-27
HU9401391D0 (en) 1994-08-29
EP0613468B1 (en) 2000-07-12
NO941799L (xx) 1994-06-22
MY130169A (en) 2007-06-29
PT101068A (pt) 1994-02-28
US5556855A (en) 1996-09-17
ZA928864B (en) 1993-05-13
PT101068B (pt) 1999-08-31

Similar Documents

Publication Publication Date Title
IL103665A (en) Analogues of sulfasalazine and their use in the preparation of a medicament having therapeutic effect against autoimmune diseases
RU94028109A (ru) Новые замещенные салициловые кислоты, способ их получения
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
FI954609A (fi) 1-amidinofenyyli-pyrrolidoneja, -piperidinoneja ja -atsetinoneja verihiutaleiden kasaantumisen inhibiittoreina
DK0638071T3 (da) Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR)
DE69413237D1 (en) Plättchenaggregationsinhibitoren
GR3025764T3 (en) Platelet aggregation inhibitors.
GB9107043D0 (en) Therapeutic agents
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
MD522G2 (ro) Noi derivaţi de piperidinii tioindol, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizare a lor ca analgezice
ES2194412T3 (es) Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento.
BR0000011A (pt) Composições injetáveis de alatrofloxacina pré-mistruadas
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
ZA202206436B (en) Macrocyclic pantetheine derivatives and uses thereof
IL108283A0 (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees